UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 23, 2010
PHARMATHENE,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32587
|
20-2726770
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
One Park Place, Suite
450, Annapolis, Maryland
|
21401
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number including area code: (410) 269-2600
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230
.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
5.07
|
Submission
of Matters to a Vote of Security
Holders.
|
At the
2010 annual meeting of stockholders of PharmAthene, Inc. (“the Company”), held
on June 23, 2010 (the “2010 Annual Meeting”), the holders of the Company’s
common stock and 10% Notes voted to elect each of the following directors to
serve until the 2011 annual meeting and until his successor is elected and
qualifies:
|
Director
|
Votes
For
|
Votes
Withheld
|
Broker
Non-Votes
|
|||
|
John
Pappajohn
|
11,758,623
|
71,091
|
9,720,062
|
|||
|
John
Gill
|
11,770,549
|
59,165
|
9,720,062
|
|||
|
Joel
McCleary
|
11,772,549
|
57,165
|
9,720,062
|
|||
|
Eric
I. Richman
|
11,811,323
|
18,391
|
9,720,062
|
|||
|
Jeffrey
W. Runge, M.D.
|
11,809,923
|
19,791
|
9,720,062
|
|||
|
Mitchel
Sayare, Ph.D.
|
11,810,923
|
18,791
|
9,720,062
|
|||
|
Derace
L. Schaffer, M.D.
|
11,810,823
|
18,891
|
9,720,062
|
|||
|
James
H. Cavanaugh, Ph.D.*
|
6,584,063
|
0
|
N/A
|
|||
|
Steven
St. Peter, M.D.*
|
6,584,063
|
0
|
N/A
|
* Noteholder
Director. “Votes For” denotes the aggregate number of shares
underlying the 10% Notes that were voted for the nominee.
At the
2010 Annual Meeting, the Company’s stockholders also voted to ratify (by a vote
of 21,286,874 to 42,591, with 220,311 votes abstaining) the selection of Ernst
& Young LLP as the Company’s independent auditors for the fiscal year ending
December 31, 2010.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PHARMATHENE,
INC.
(Registrant)
|
|||
|
Date:
June 29, 2010
|
By:
|
/s/
Jordan P. Karp
|
|
|
Jordan
P. Karp
|
|||
|
Senior
Vice President, General Counsel and Secretary
|
|||